Fibrinolysis in Myocardial Infarction: Lessons for Cerebrovascular Disease

  • J. Meyer
Conference paper

Abstract

Until about 15 years ago the prevailing view of the pathogenesis of acute myocardial infarction was that it was based on total or subtotal atherosclerotic coronary obstructions causing a major decrease in antegrade flow. Fresh thrombi, which were often found during autopsy, were thought to be the result rather than the cause of the infarction [4], With the increasing availability of coronary arteriography for acute myocardial infarction came a major change in the understanding of the pathophysiology of the disease. DeWood et al. [9], using serial coronary arteriograms, showed that a fresh, occluding coronary thrombus is the cause and can be found in the majority of acute myocardial infarctions. While within the first 6 h the rate of total occlusions was 85%, this fell to 68% in the 6th–12th h — and to 64% in the 12th–24th h. These results also demonstrated that spontaneous thrombolysis occurs in about 20% of all patients within the 1st day.

Keywords

Superoxide Aspirin Heparin Coumadin Expense 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    AIMS Trial Study Group (1988) Effect of intravenous APS AC on mortality after acute myocardial infarction. Lancet i:545–549Google Scholar
  2. 2.
    Althouse R, Maynard C, Olsufka M, Kennedy JW (1988) Incidence of contraindications to thrombolysis in patients with myocardial infarction. Circulation 78(Suppl II) 211Google Scholar
  3. 3.
    Anderson JL, Marshall HW, Bray BE dute JR, Frederick PR, Yanowite FG, Date FL, Klausner SC, Hagan AD (1983) A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 308:1312–1318PubMedCrossRefGoogle Scholar
  4. 4.
    Baroldi G (1976) Coronary thrombosis:facts and beliefs. Am Heart J 91:683–688PubMedCrossRefGoogle Scholar
  5. 5.
    Bonnier HJRM, Visser RF, Klamps HC, Hoffmann HJML (1988) Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Am J Cardiol 61:25–30CrossRefGoogle Scholar
  6. 6.
    Braunwald E, Kloner RA (1982) The stunned myocardium prolonged, postischemic ventricular dysfunction. Circulation 66:1146–1149PubMedCrossRefGoogle Scholar
  7. 7.
    Chazov EJ, Mateeva LS, Mazaev AV, Sargin KE, Sadovskaya GV, Ruda MY (1976) Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh 48: 8–19PubMedGoogle Scholar
  8. 8.
    Chesebro JH, Knatterud G, Roberts R Borery, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Huellerth, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel E, Willerson J, Williams DO, Qaret BL, Brannwald E (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I:a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142–154PubMedCrossRefGoogle Scholar
  9. 9.
    Wood MA de, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902CrossRefGoogle Scholar
  10. 10.
    Erbel R, Pop T, Meinertz T, Kasper W, Schreiner G, Henkel B, Henrichs KJ, Pfeiffer C, Rupprecht HJ, Meyer J (1985) Combined medical and mechanical recanalization in acute myocardial infarction. Cathet Cardiovasc Diagn 11:361–377PubMedCrossRefGoogle Scholar
  11. 11.
    Gruppo Italiano per lo Studio della Streptochinasi nell Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocadial infarction. Lancet i:397–402Google Scholar
  12. 12.
    ISIS Steering Committee (1987) Intravenous streptokinase given within 0–4 hours of onset of myocardial infarction reduced mortality in ISIS-2. Lancet i:502CrossRefGoogle Scholar
  13. 13.
    ISIS-2 Collaborative Groups (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet ii:349–360Google Scholar
  14. 14.
    Kennedy JW, Ritchie JL, Davis KB, Fritz JK (1983) Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 309:1477–1481PubMedCrossRefGoogle Scholar
  15. 15.
    Kennedy JW, Martin GV, Davis KB, Maynard C, Stadius M, Sheehan FH, Ritchie JL (1988) The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 77:345–352PubMedCrossRefGoogle Scholar
  16. 16.
    Magnani B, for the PAIMS Investigastors (1989) Plasminogen activator Italian multi- center study (PAIMS) comparison of intravenous recombinant single-chain humantissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 13:19–26PubMedCrossRefGoogle Scholar
  17. 17.
    Mathey DG, Schofer J, Sheehan FH, Becker H, Tilsner V, Dodge HT (1985) Intravenous urokinase in acute myocardial infarction. Am J Cardiol 55:878–882PubMedCrossRefGoogle Scholar
  18. 18.
    Meinertz T, Kasper W, Schumacher M, Just H, for the APSAC Multicenter Trial Group (1988) The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 62:347–351PubMedCrossRefGoogle Scholar
  19. 19.
    Meyer J, Merx W, Schmitz H, Erbel R, Kiesslich T, Dörr R, Lambertz H, Bethge C, Krebs W, Bardos P, Minale C, Messmer BJ, Effert S (1982) Percutaneous transluminal coronary angioplasty immediate after intracoronary streptolysis of transmural myocardial infarction. Circulation 66:905–913PubMedCrossRefGoogle Scholar
  20. 20.
    Neuhaus KL, Tebbe U, Gottwik M, Weber MAJ, Feurer W, Niederer W, Haerer W, Praetorius F, Grosser KD, Huhmann W, Hoepp HW, Alber G, Sheikhzadeh JA, Schneider B (1988) Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction:results of the German activator urokinase study (GAUS). J Am Coll Cardiol 12:581–587PubMedGoogle Scholar
  21. 21.
    Primi Trial Study Group (1989) Randomized double-blind trial of recombinant pro- urokinase against streptokinase in acute myocardial infarction. Lancet i:863–868Google Scholar
  22. 22.
    Rao AK (1988) Thrombolysis in myocardial infarction (TIMI) trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11PubMedCrossRefGoogle Scholar
  23. 23.
    Rentrop P, Blanke H, Karsch KR, Wiegand V, Köstering H, Rahlf G, Oster H, Leitz K (1979) Wiedereröffnung des Infarktgefäßes durch transluminale Rekanalisation und intrakoronare Streptokinase-Applikation. Dtsch Med Wochenschr 104:1438–1440PubMedCrossRefGoogle Scholar
  24. 24.
    Rutsch W, Schartl M, Mathey D, Kuck K, Merx W, Dörr R, Rentrop P, Blanke H, Karsch K (1982) Perkutane, transluminale, koronare Rekanalisation: Methodik, Ergebnisse und Komplikationen. Z Kardiol 71:7–13PubMedGoogle Scholar
  25. 25.
    Santoro GM, Bisi G, Sciagra R, Leoncini M, Fazzini PF, Meldolesi V (1990) Single photon emission computed tomography with technetium-9 m hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before and after thrombolytic treatment - assessement of salvaged myocardium and prediction of late functional recovery. J Am Coll Cardiol 15:301–314PubMedCrossRefGoogle Scholar
  26. 26.
    Schröder R, Biamino G, von Leitner ER, Linderer T (1981) Intravenöse Streptokinase- Infusion bei akutem Myokardinfarkt. Dtsch Med Wochenschr 106:294–301PubMedCrossRefGoogle Scholar
  27. 27.
    Simoons ML, van den Brand M, de Zwan C, Verhengt FWA, Remme WJ, Serruys PW, Bär F, Res J, Krauss XH, Vermeer F, Lubsen J (1985) Improved survival after early thrombolysis in acute myocardial infarction. Lancet ii:578–581CrossRefGoogle Scholar
  28. 28.
    TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial phase I findings. N Engl J Med 312:932–936Google Scholar
  29. 29.
    TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320:618–627CrossRefGoogle Scholar
  30. 30.
    van de Werf F, Arnold AER (1988) Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 297:1374–1379CrossRefGoogle Scholar
  31. 31.
    Verstraete M, Bernard R, Bory M, Brower RW, Collen D, deBono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R (1985) Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet ii:842–847CrossRefGoogle Scholar
  32. 32.
    White CW (1989) Recurrent ischemic events after successful thrombolysis in acute myocardial infarction. Circulation 80:1482–1485PubMedCrossRefGoogle Scholar
  33. 33.
    White HD, Norris RM, Brown MA (1987) Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 317:850–855PubMedCrossRefGoogle Scholar
  34. 34.
    Yusuf S, Collins R, Peto R, Furberg C, Stampter MJ, Goldhaber SZ, Hennekens CH (1985) Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials. Eur Heart J 6:556–585PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • J. Meyer
    • 1
  1. 1.Second Medical University ClinicMainz 1Germany

Personalised recommendations